Approved Drugs for Psychiatry/Psychology
Edluar (zolpidem tartrate); Orexo;
For the treatment of insomnia, Approved March 2009
Fanapt (iloperidone); Vanda;
For the treatment of schizophrenia, Approved May of 2009
Intuniv (guanfacine extended-release); Shire;
For the treatment of ADHD in children and adolescents, Approved September 2009
Saphris (asenapine); Schering-Plough;
For the treatment of schizophrenia and manic or mixed bipolar 1 episodes, Approved August of 2009
Aplenzin (bupropion hydrobromide); Biovail Laboratories;
For the treatment of major depressive disorder, Approved April 2008
Stavzor (valproic acid delayed release); Banner Pharmacaps;
For the treatment of bipolar manic disorder, seizures and migraine headaches, Approved July 2008
Vyvanse (Lisdexamfetamine Dimesylate); New River;
For the treatment of Attention-Deficit/Hyperactivity Disorder, Approved February 2007
Chantix (varenicline); Pfizer;
For the treatment of nicotine addiction, Approved May 2006
Invega (paliperidone); Janssen Pharmaceutica;
For the treatment of schizophrenia, Approved December 2006
Cymbalta (duloxetine); Eli Lilly;
For the treatment of major depressive disorder, Approved August 2004
Abilify (aripiprazole); Bristol-Myers Squibb, Otsuka America Pharmaceutical;
Oral drug for the treatment of schizophrenia, Approved November 2002
Geodon (ziprasidone mesylate); Pfizer;
To control agitated behavior and psychotic symptoms in schizophrenia patients, Approved June 2002
Lexapro (escitalopram oxalate); Forest Laboratories;
An orally administered selective serotonin reuptake inhibitor useful for the treatment for major depressive disorder, Approved August 2002
Paxil CR (paroxetine hydrochloride); GlaxoSmithKline;
Oral tablet for the treatment of depression and panic disorder, Approved February 2002
Ritalin LA (methylphenidate HCl); Novartis;
Oral capsules for the treatment Attention-Deficit/Hyperactivity Disorder (ADHD), Approved June 2002
Strattera (atomoxetine HCl); Eli Lilly;
For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents and adults., December 2002
Subutex/Suboxone (buprenorphine/naloxone); Reckitt Benckiser;
Oral tablets for the treatment of opiate dependence, Approved October 2002
Zoloft (sertraline HCl); Pfizer;
Oral tablets for the treatment of premenstrual dysphoric mood disorder (PMDD), Approved May 2002
Adderall XR; Shire Pharmaceuticals;
Once-daily medication for the treatment of attention deficit/hyperactivity disorder (ADHD), Approved October 2001
Focalin (dexmethylphenidate HCl); Celgene;
For the treatment of attention deficit hyperactivity disorder (ADHD), Approved November 2001
Metadate CD; Celltech Pharmaceuticals;
Oral capsules for the treatment of attention deficit hyperactivity disorder, Approved April 2001
Prozac Weekly (fluoxetine HCl); Eli Lilly;
For the treatment of depression, Approved February 2001
Remeron SolTab (mirtazapine); Organon;
Orally disintegrating tablet for the treatment of depression, Approved January 2001
Ziprasidone (ziprasidone hydrochloride); Pfizer;
Oral capsule for the treatment of schizophrenia, Approved February 2001
Concerta; Alza;
For the treatment of Attention Deficit Hyperactivity Disorder, Approved August 2000
Effexor (venlafaxin HCL); Wyeth;
Treatment for generalized anxiety disorder, Approved March 1999
Paxil CR (paroxetine hydrochloride); SmithKline Beecham;
Treatment for depression, Approved March 1999
Sonata; American Home Products;
Treatment fo insomnia, Approved August 1999
Celexa; Forest Laboratories;
Treatment for depression, Approved July 1998
Clomipramine hydrochloride; Mylan Laboratories;
Generic equivalent of Anafranil, Approved April 1998
Cylert; Abbott Laboratories;
Treatment for Attention Deficit Disorder, Approved October 1998
Marplan Tablets; Roche;
Treatment of Depression, Approved August 1998
Naltrexone Hydrochloride Tablets; Barr Laboratories;
Generic equivalent of Revia, Approved May 1998
Prochlorperazine; IVAX;
Generic equivalent of SmithKline Beecham's Compazine, Approved January 1998
Effexor XR (venlafaxin HCI); Wyeth;
Treatment of depression, Approved October 1997
Generic Transdermal Nicotine Patch; Sano;
Generic equivalent of Habitrol, Approved October 1997
LUVOX (fluvoxamine maleate); Solvay Pharmaceuticals, Pharmacia & Upjohn;
Treatment for obsessive compulsive disorder (OCD) in children and adolescents, Approved April 1997
Seroquel (R) (quetiapine fumarate) Tablets; AstraZeneca;
Treatment for schizophrenia, Approved September 1997
Trazadone 150mg; Teva Pharmaceutical;
Generic equivalent of Desyrel 7, Approved May 1997
Zoloft (sertraline HCl); Pfizer;
Treatment for panic disorder, Approved July 1997
Zoloft (sertraline HCl); Pfizer;
Treatment of panic disorder in children ages 6-17, Approved October 1997
Zyban Sustained-Release Tablets; GlaxoSmithKline;
Treatment for smoking cessation, Approved May 1997
Adderall (mixed salts of a single-entity amphetamine); Richwood Pharmaceutical;
Treatment for attention-deficit/hyperactivity disorder, Supplemental NDA Approved February 1996
ARICEPT (donepezil hydrochloride); Eisai;
Treatment for Alzheimer's Disease, Approved December 1996
Depakote (divalproex sodium); Abbott Laboratories;
Treatment for migraine headaches, Approved March 1996
Lithobid (Lithium Carbonate); Solvay Pharmaceuticals;
Treatment for manic depression, Approved January 1996
NicoDerm CQ; SmithKline Beecham, Hoechst Marion Roussel, Alza;
Treatment for smoking cessation, Approved August 1996
Nicorette (nicotine polacrilex); SmithKline Beecham;
Over-the-counter aid in smoking cessation, Approved February 1996
Nicotrol nasal spray; Pharmacia & Upjohn;
Treatment for nicotine addiction, Approved March 1996
Nicotrol transdermal patch; McNeil Consumer Products;
Treatment for smoking cessation, Approved July 1996
Paxil (paroxetine hydrochloride); SmithKline Beecham;
Treatment for panic disorder, Approved May 1996
Redux (dexfenfluramine hydrochloride); Wyeth;
Treatment for obesity, Approved May 1996
Remeron (Mirtazapine); Organon;
Treatment for depression, Approved June 1996
Risperdal Oral Formulation; Janssen Pharmaceutica;
Treatment for schizophrenia, Approved July 1996
Zyprexa; Eli Lilly;
Treatment of the symptoms of psychotic disorders, Approved September 1996
